MA40283A - Aptamères spécifiques du récepteur tlr-4 et leurs utilisations - Google Patents
Aptamères spécifiques du récepteur tlr-4 et leurs utilisationsInfo
- Publication number
- MA40283A MA40283A MA040283A MA40283A MA40283A MA 40283 A MA40283 A MA 40283A MA 040283 A MA040283 A MA 040283A MA 40283 A MA40283 A MA 40283A MA 40283 A MA40283 A MA 40283A
- Authority
- MA
- Morocco
- Prior art keywords
- tlr
- aptamer
- specific aptamers
- receiver specific
- methods
- Prior art date
Links
- 108091023037 Aptamer Proteins 0.000 title abstract 3
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 title 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000000524 functional group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 108091008104 nucleic acid aptamers Proteins 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
- G01N2800/164—Retinal disorders, e.g. retinopathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201430955A ES2555160B1 (es) | 2014-06-24 | 2014-06-24 | Aptámeros específicos de TLR-4 y usos de los mismos |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA40283A true MA40283A (fr) | 2017-05-03 |
Family
ID=53496661
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA040283A MA40283A (fr) | 2014-06-24 | 2015-06-24 | Aptamères spécifiques du récepteur tlr-4 et leurs utilisations |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US10196642B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3161139B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6959738B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102454682B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN112111495A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015279248B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112016030172B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2953020C (cg-RX-API-DMAC7.html) |
| DK (1) | DK3161139T3 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2555160B1 (cg-RX-API-DMAC7.html) |
| MA (1) | MA40283A (cg-RX-API-DMAC7.html) |
| MX (1) | MX387405B (cg-RX-API-DMAC7.html) |
| PL (1) | PL3161139T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3161139T (cg-RX-API-DMAC7.html) |
| RU (1) | RU2709718C9 (cg-RX-API-DMAC7.html) |
| SI (1) | SI3161139T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015197706A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201700363B (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015155178A1 (en) * | 2014-04-07 | 2015-10-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New method for producing outer membrane vesicles |
| ES2555160B1 (es) * | 2014-06-24 | 2016-10-25 | Aptus Biotech, S.L. | Aptámeros específicos de TLR-4 y usos de los mismos |
| WO2018014012A1 (en) | 2016-07-15 | 2018-01-18 | President And Fellows Of Harvard College | Glycolipid compositions and methods of use |
| EP3494994A1 (en) * | 2017-12-07 | 2019-06-12 | Universität zu Köln | Combinations of ripk1- and ikk-inhibitors for the prevention or treatment of immune diseases |
| JP2021535739A (ja) | 2018-08-27 | 2021-12-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 下流精製でのラマン分光法の使用 |
| IL281135B2 (en) | 2018-09-28 | 2024-12-01 | Nutcracker Therapeutics Inc | Tertiary amino lipidated cationic peptides for nucleic acid delivery |
| KR20210096599A (ko) * | 2018-09-28 | 2021-08-05 | 어그매니티 나노 엘티디 | 기능적 압타머의 선택을 위한 방법 및 조성물 |
| WO2020069569A1 (en) | 2018-10-02 | 2020-04-09 | WearOptimo Pty Ltd | Actuator system |
| US12048558B2 (en) | 2018-10-02 | 2024-07-30 | WearOptimo Pty Ltd | System for determining fluid level in a biological subject |
| US20220233570A1 (en) * | 2019-05-16 | 2022-07-28 | Aptatargets, S.L. | Treatment of ischemic stroke with aptamers targeting tlr-4 |
| CN111474336B (zh) * | 2020-03-21 | 2023-07-28 | 南昌大学 | 一种铁氰化镍纳米粒化学发光适体传感器的制备方法及基于其检测8-OhdG的方法 |
| WO2021257494A1 (en) * | 2020-06-15 | 2021-12-23 | President And Fellows Of Harvard College | Methods for modulating tlr4 signaling |
| CN114152599B (zh) * | 2021-12-01 | 2023-10-13 | 中国农业大学 | 一种基于双劈裂功能核酸变构的孔雀石绿生物传感器 |
| CN114836425A (zh) * | 2022-02-25 | 2022-08-02 | 温州医科大学附属眼视光医院 | 检测小胶质细胞的核酸适体及应用 |
| IL321911A (en) | 2023-01-05 | 2025-09-01 | Merck Patent Gmbh | Aptol molecules for the treatment of ischemic stroke and intracranial hemorrhages |
| AU2024275027A1 (en) | 2023-05-22 | 2025-12-11 | Merck Patent Gmbh | New tlr-4 antagonist aptamers |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5194599A (en) | 1988-09-23 | 1993-03-16 | Gilead Sciences, Inc. | Hydrogen phosphonodithioate compositions |
| US5264562A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences, Inc. | Oligonucleotide analogs with novel linkages |
| EP0549686A4 (en) | 1990-09-20 | 1995-01-18 | Gilead Sciences Inc | Modified internucleoside linkages |
| AU784335B2 (en) * | 2000-02-03 | 2006-03-16 | Research Development Foundation | Signaling aptamers that transduce molecular recognition to differential signal |
| US20060257411A1 (en) * | 2005-05-06 | 2006-11-16 | Bruce Beutler | Compositions and methods for modulating cells via CD14 and toll-like receptor 4 signaling pathway |
| CN101227922A (zh) * | 2005-05-06 | 2008-07-23 | 斯克里普斯研究学院 | 经由CD14和Toll样受体4信号传导途径调节细胞的组合物和方法 |
| EP1895842A4 (en) * | 2005-06-17 | 2009-06-03 | Univ Rochester | METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE MEMORY BY BLOCKING INTRAHEPATIC ERASURE OF ACTIVE T CELLS |
| FR2892730A1 (fr) * | 2005-10-28 | 2007-05-04 | Biomerieux Sa | Methode pour detecter la presence ou le risque de developper un cancer |
| US20090317802A1 (en) * | 2005-12-09 | 2009-12-24 | Bhatia Sangeeta N | Compositions and Methods to Monitor RNA Delivery to Cells |
| US9012410B2 (en) * | 2006-12-13 | 2015-04-21 | Case Western Reserve University | Method of treating intrauterine inflammation |
| AU2009313604A1 (en) | 2008-11-04 | 2010-05-14 | Idera Pharmaceuticals, Inc. | Modulation of toll-like receptor 4 expression by antisense oligonucleotides |
| WO2010060030A1 (en) | 2008-11-24 | 2010-05-27 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona | Tlr ligand-nucleic acid nanostructure as a novel immune modulatory agent and method of using the same |
| CN103562387A (zh) * | 2011-03-03 | 2014-02-05 | 夸克医药公司 | Toll样受体途径的寡核苷酸调剂 |
| CA2828002A1 (en) * | 2011-03-03 | 2012-09-07 | Quark Pharmaceuticals, Inc. | Compositions and methods for treating lung disease and injury |
| ES2555160B1 (es) * | 2014-06-24 | 2016-10-25 | Aptus Biotech, S.L. | Aptámeros específicos de TLR-4 y usos de los mismos |
-
2014
- 2014-06-24 ES ES201430955A patent/ES2555160B1/es not_active Expired - Fee Related
-
2015
- 2015-06-24 US US15/322,021 patent/US10196642B2/en active Active
- 2015-06-24 MX MX2016016992A patent/MX387405B/es unknown
- 2015-06-24 CN CN202010953057.9A patent/CN112111495A/zh active Pending
- 2015-06-24 RU RU2016152094A patent/RU2709718C9/ru active
- 2015-06-24 PL PL15732619T patent/PL3161139T3/pl unknown
- 2015-06-24 WO PCT/EP2015/064277 patent/WO2015197706A1/en not_active Ceased
- 2015-06-24 SI SI201531392T patent/SI3161139T1/sl unknown
- 2015-06-24 AU AU2015279248A patent/AU2015279248B2/en active Active
- 2015-06-24 EP EP15732619.0A patent/EP3161139B1/en active Active
- 2015-06-24 ES ES15732619T patent/ES2825106T3/es active Active
- 2015-06-24 PT PT157326190T patent/PT3161139T/pt unknown
- 2015-06-24 BR BR112016030172-2A patent/BR112016030172B1/pt active IP Right Grant
- 2015-06-24 CN CN201580034070.1A patent/CN106459980B/zh active Active
- 2015-06-24 DK DK15732619.0T patent/DK3161139T3/da active
- 2015-06-24 KR KR1020177001493A patent/KR102454682B1/ko active Active
- 2015-06-24 JP JP2016575345A patent/JP6959738B2/ja active Active
- 2015-06-24 MA MA040283A patent/MA40283A/fr unknown
- 2015-06-24 CA CA2953020A patent/CA2953020C/en active Active
-
2017
- 2017-01-17 ZA ZA2017/00363A patent/ZA201700363B/en unknown
-
2018
- 2018-12-14 US US16/220,726 patent/US10808252B2/en active Active
-
2020
- 2020-05-07 JP JP2020082070A patent/JP2020127422A/ja active Pending
- 2020-09-16 US US17/022,984 patent/US11591603B2/en active Active
-
2023
- 2023-01-19 US US18/156,936 patent/US20230279402A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA40283A (fr) | Aptamères spécifiques du récepteur tlr-4 et leurs utilisations | |
| MA49726B1 (fr) | Formulation d'anticorps anti-cgrp | |
| EA201501032A1 (ru) | Фармацевтическая композиция, способы лечения и ее применения | |
| MA38406B1 (fr) | Virus de la maladie de newcastle et leurs utilisations | |
| WO2018069500A3 (en) | Anti-lag-3 antibodies and compositions | |
| MA43187A (fr) | Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations | |
| EA201792047A1 (ru) | Новые соединения | |
| MA41013B1 (fr) | Compositions comprenant des souches bactériennes | |
| EA201491656A1 (ru) | Связывающие молекулы человека, способные связываться с вирусами гриппа в и нейтрализовать их, и их применения | |
| MA38554A3 (fr) | Anticorps bispécifiques dirigés contre fap et dr5, anticorps spécifiques dirigés contre dr5 et leurs procédés d'utilisation | |
| MA44637A1 (fr) | Composes hétérocycliques et leurs utilisations | |
| MA46619B1 (fr) | Anticorps anti-il-33 et leurs utilisations | |
| PH12016501307A1 (en) | Compounds | |
| MA38567A1 (fr) | Variantes de pertuzumab et leur évaluation | |
| MA35130B1 (fr) | Composition comprenant de l'aflibercept, de l'acide folinique, du 5-fluoro-uracile (5-fu) et de l'irinocetan (folfiri) | |
| PH12018500578A1 (en) | Methods of treating inflammatory diseases | |
| EA201591379A1 (ru) | Липопротеин-ассоциированные ингибиторы фосфолипазы a2 (lp-pla) на основе 2,3-дигидроимидазо[1,2-с]пиримидин-5(1h)-онов | |
| MA39170A1 (fr) | Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer | |
| HK1207970A1 (en) | Agents for influenza neutralization | |
| FR3058059B1 (fr) | Composition pharmaceutique comprenant le beta-elemene, le lupeol et le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine. | |
| WO2018071504A3 (en) | Methods of treating diseases with il-23a antibody | |
| AU2017261919A1 (en) | Fat and medical uses thereof | |
| MA40844A (fr) | Compositions pharmaceutiques à action prolongée pour l'hépatite c | |
| FR3074421B1 (fr) | Extrait d'helichrysum gymnocephalum pour le traitement et/ou la prevention des dermatoses inflammatoires | |
| FR3058060B1 (fr) | Composition pharmaceutique comprenant le beta-elemene, le lupeol, le cinnamaldehyde et/ou le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine. |